Adelaide-based Australian biotechnology company Sementis has appointed former AusBiotech CEO and Medicines Australia chair Dr Anna Lavelle as an independent director.
The company is currently partnering with the University of South Australia on the development of a next-generation Covid-19 vaccine based on the Sementis Copenhagen Vector (SCV) platform.
The company said its vaccine is intended to provide an Australian-owned and developed vaccine technology.
Sementis chair Martyn Evans said, “Dr Lavelle brings an extraordinary wealth of experience and knowledge to our work at Sementis in developing world-leading vaccines.
“She will be of great assistance in bringing a clear focus on the strategic priorities for the company and our milestones going forward. I welcome Dr Lavelle to the board and look forward to working with her.”